These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 19917368)

  • 1. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation.
    Brown CM; Abraham KA; O'Kelly P; Conlon PJ; Walshe JJ
    Transplant Proc; 2009 Nov; 41(9):3690-2. PubMed ID: 19917368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of rituximab therapy for treatment of acute humoral rejection.
    Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
    Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.
    Tanriover B; Wright SE; Foster SV; Roush KS; Castillo-Lugo JA; Fa K; Levy FL; Mejia A
    Transplant Proc; 2008 Dec; 40(10):3393-6. PubMed ID: 19100397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL; Murillo D
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal therapy with combined plasmapheresis, photoapheresis, and intravenous immunoglobulin for acute antibody-mediated renal transplant rejection: a 2-year follow-up.
    Lai Q; Pretagostini R; Gozzer M; Cinti P; Meo D; Vita F; Shafii Bafti M; Poli L; Novelli G; Rossi M; Girelli G; Berloco PB
    Transplant Proc; 2011 May; 43(4):1039-41. PubMed ID: 21620047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
    Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
    Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience.
    Slatinska J; Honsova E; Burgelova M; Slavcev A; Viklicky O
    Ther Apher Dial; 2009 Apr; 13(2):108-12. PubMed ID: 19379149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation.
    Lehrich RW; Rocha PN; Reinsmoen N; Greenberg A; Butterly DW; Howell DN; Smith SR
    Hum Immunol; 2005 Apr; 66(4):350-8. PubMed ID: 15866697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmapheresis as rescue therapy in accelerated acute humoral rejection.
    Abraham KA; Brown C; Conlon PJ; Donohoe J; Hickey DP; O'Neill D; Keogan MT; Dorman AM; Walshe J
    J Clin Apher; 2003; 18(3):103-10. PubMed ID: 14569599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of donor age and acute rejection episodes on long-term graft survival in cadaveric kidney transplantations.
    Emiroğlu R; Yagmurdur MC; Karakayali F; Haberal C; Ozcelik U; Colak T; Haberal M
    Transplant Proc; 2005 Sep; 37(7):2954-6. PubMed ID: 16213272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection.
    Mulley WR; Hudson FJ; Tait BD; Skene AM; Dowling JP; Kerr PG; Kanellis J
    Transplantation; 2009 Jan; 87(2):286-9. PubMed ID: 19155986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.
    Ibernón M; Gil-Vernet S; Carrera M; Serón D; Moreso F; Bestard O; Cruzado JM; Grinyó JM
    Transplant Proc; 2005 Nov; 37(9):3743-5. PubMed ID: 16386524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloantibodies and the outcome of cadaver kidney allografts.
    Vasilescu ER; Ho EK; Colovai AI; Vlad G; Foca-Rodi A; Markowitz GS; D'Agati V; Hardy MA; Ratner LE; Suciu-Foca N
    Hum Immunol; 2006 Aug; 67(8):597-604. PubMed ID: 16916655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current approaches to treatment of antibody-mediated rejection.
    Jordan SC; Vo AA; Tyan D; Nast CC; Toyoda M
    Pediatr Transplant; 2005 Jun; 9(3):408-15. PubMed ID: 15910400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
    Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
    Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.